Serum LOX-1 (sLOX-1) is a potential biomarker for acute coronary syndromes (ACS), T2D, stroke and metabolic syndromes such as obesity: there is potential for integrating such biomarker use into routine clinical practice and patient monitoring [256,257,258]. Here, OLR1 is linked to acute coronary syndrome.